XOMA’s Cash Infusion and Commitment to Shareholders Amidst Stock Performance Challenges
EMERYVILLE, Calif. June 12, 2024 - XOMA Corporation (NASDAQ: XOMA), a biotech royalty aggregator, recently received an $8.1 million milestone payment from Viracta Therapeutics, Inc. following the sale of Day One Biopharmaceuticals’ Priority Review Voucher (PRV) for $108 million to an undisclosed buyer. This significant cash infusion comes at a crucial time for XOMA as the company has been grappling with a cumulative net loss of $-45 million over the past 12 months, resulting in a negative return on assets (ROA) of -25.64%.Despite these financial challenges, XOMA Corporation remains optimistic about its future prospects. Within the healthcare sector, although 280 other companies have a higher return on assets, XOMA’s ROA ranking has improved from 3327 in the fourth quarter of 2023 to 2667 in the first quarter of 2024. This improvement suggests that the company’s efforts to turn its financial situation around might be yielding some positive results.
Furthermore, the recent announcement of cash dividends for holders of XOMA’s Series A and Series B Cumulative Preferred Stock demonstrates the company’s commitment to rewarding its shareholders. The quarterly preferred stock dividends serve as an additional incentive for investors to hold onto their shares, reinforcing XOMA’s dedication to maintaining a strong relationship with its investors.
Within this challenging period for XOMA’s stock performance, the company’s shares have experienced a decline of -3.75% over the past week and a year-to-date performance of -16.08%. However, there is a silver lining as the stock is currently trading 14.5% above its 52-week low. This upward trend indicates that although XOMA has had its share of struggles, its stock value has shown signs of resilience.
In conclusion, XOMA Corporation’s recent milestone payment from Viracta Therapeutics, in addition to the declaration of cash dividends for preferred stockholders, highlights the company’s commitment to maintaining a strong relationship with its investors despite its troubled stock performance. These positive developments, along with XOMA’s improving ROA ranking, provide a glimmer of hope for the biotech royalty aggregator’s future prospects.
Comments